05.07.19
Mylan
1Q Revenues: $2.5 billion (-7%)
1Q Loss: $25 million (earnings were $87.1 million)
Comments: North America sales were $922.9 million, down 6% primarily driven by changes in the competitive environment and the impact of the Morgantown plant remediation activities, partially offset by new product sales, including Wixela Inhuband Fulphila (biosimilar to Neulasta), and increased market share on Glatiramer Acetate Injection. Rest of World segment sales were $642.4 million, up 3%. Europe segment sales were $895.3 million, down 14%. Mylan's sales were unfavorably impacted by foreign currency translation, primarily reflecting changes in the U.S. Dollar as compared to the currencies of Mylan's subsidiaries in India, Australia, and the EU.
1Q Revenues: $2.5 billion (-7%)
1Q Loss: $25 million (earnings were $87.1 million)
Comments: North America sales were $922.9 million, down 6% primarily driven by changes in the competitive environment and the impact of the Morgantown plant remediation activities, partially offset by new product sales, including Wixela Inhuband Fulphila (biosimilar to Neulasta), and increased market share on Glatiramer Acetate Injection. Rest of World segment sales were $642.4 million, up 3%. Europe segment sales were $895.3 million, down 14%. Mylan's sales were unfavorably impacted by foreign currency translation, primarily reflecting changes in the U.S. Dollar as compared to the currencies of Mylan's subsidiaries in India, Australia, and the EU.
